Ireland
--:--IST
Recruiting Not applicable

Multimodal Quantified Analysis of Facial Movements: Comparison Between Pathological and Control Subjects

NCT05581680 · tracked via the Priya Life Science France tracker
Phase
Not applicable
Started
2022-10-12
Last updated
2025-05-28

Condition(s) studied

ElectromyographyEye-trackingFacial Palsy

Investigational drug(s) / intervention(s)

dental impressionsSimultaneous MoCap and EMG acquisitionEye-tracking acquisition for pathological subjectsFollow-up visit for pathological subjects

dental impressions: dental impressions

Simultaneous MoCap and EMG acquisition: Simultaneous MoCap and EMG acquisition

Eye-tracking acquisition for pathological subjects: Eye-tracking acquisition for pathological subjects

Follow-up visit for pathological subjects: Follow-up visit for pathological subjects

Study summary

The facial palsy is a frequent disease with a lot of etiologies. It has variable severities with sometimes heavy functional repercussions and different recovery potentials. The proposed treatments are based on surgery, physiotherapy and botulinum toxin injections. However, when recovery is incomplete, acceptance is more difficult, with an impacted quality of life. Thanks to Motion Capture and Electromyography, a quantification of the facial mimicry is now possible with a great precision. In addition with the quantification of the facial mimicry, eye-tracking, wich is widely used in the marketing field, but it also finds medical applications including head and neck lesions and facial palsy in particular, will be used to evaluate the visio of the patients on their pathology in function of the movement quantification measured with MoCap and Electromyography. The aim of this research is to measure in a combined way the action potentials by sEMG and the amplitudes of displacement of the markers in motion capture, for movements determined in a population of patients presenting a facial pathology, in order to compare them with reference values obtained in healthy subjects. In a second step, the aim will be to study if there is a link between the way the patient looks at his pathology and the results of his management (treatment, rehabilitation) which will be quantitatively evaluated thanks to MoCap and sEMG.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria: * Subjects with no known facial pathology (healthy volunteers) OR * Patients with peripheral facial palsy, irrespective of grade, whether or not previously treated * Subject with written informed consent * Subject over 18 years of age * Subject affiliated to a social security scheme Exclusion Criteria: * Subjects with severe skin disorders that do not allow the application of electrodes or photo reflective markers * Subjects with speech disorders making it impossible to pronounce the sounds \[o\] and \[pu\] * Subject unable to provide written informed consent * Subjects under guardianship, curators or safeguard of justice

Primary outcome measure(s)

  • determination of baseline values of facial mimicry (in millimetres) in healthy volunteers — one month
    determination of baseline values of facial mimicry (in millimetres) in healthy volunteers
  • determination of baseline values of eye-tracking (in millimetres) in healthy volunteers — one month
    determination of baseline values of eye-tracking (in millimetres) in healthy volunteers
  • determination of the maximum range of motion of facial mimicry (in millimetres) in patients — one year
    determination of the maximum range of motion facial mimicry (in millimetres) in patients
  • determination of the maximum range of motion of eye-tracking (in millimetres) in patients — one year
    determination of the maximum range of motion of eye-tracking (in millimetres) in patients

Trial sites (1)

FacilityCityRegionStatus
CHU Amiens Picardie Amiens Picardie Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05581680 on ClinicalTrials.gov ↗ ← All trials in France